Research analysts at MLV & Co began coverage on shares of ImmunoCellular Therapeutics Ltd (NASDAQ: IMUC) in a report released on Tuesday. The firm set a “buy” rating and a $4.50 price target on the stock.
A number of other analysts have also recently weighed in on IMUC. Analysts at Cowen initiated coverage on shares of ImmunoCellular Therapeutics Ltd in a research note to investors on Friday, February 17th. They set a “neutral” rating on the stock.
ImmunoCellular Therapeutics, Ltd. is a development-stage company. The Company is seeking to develop and commercialize new therapeutics to fight cancer using the immune system.